NCT03258164 is a Phase 3 clinical trial of ASC enriched lipofilling in Breast Hypoplasia and Facial Ageing, sponsored by Stemform.

Who is sponsoring NCT03258164?

NCT03258164 is sponsored by Stemform.

What drugs are being tested in NCT03258164?

Interventions in NCT03258164: ASC enriched lipofilling, Standard Lipofilling.

What condition does NCT03258164 study?

NCT03258164 studies Breast Hypoplasia and Facial Ageing.

Is NCT03258164 still recruiting?

NCT03258164 is currently completed. Last updated 28 November 2022.

Last reviewed 2022-11-28 · How we verify

NCT03258164

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cosmetic Fat Transplantation Using Expanded ASC Enriched Fat Grafts

Completed Phase 3 Last updated 28 November 2022

What this trial tests

Phase 3 trial testing ASC enriched lipofilling in Breast Hypoplasia and Facial Ageing in 32 participants. Completed in 22 November 2022.

Timeline

22 March 2017

Primary endpoint
24 October 2022

22 November 2022

Quick facts

Lead sponsor	Stemform
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	32
Start date	22 March 2017
Primary completion	24 October 2022
Estimated completion	22 November 2022
Sites	1 location across Denmark

Drugs / interventions tested

ASC enriched lipofilling — full drug profile →
Standard Lipofilling — full drug profile →

Conditions studied

Breast Hypoplasia and Facial Ageing — all drugs for Breast Hypoplasia and Facial Ageing →

Sponsor

Stemform — full company profile →

Who can join

Adults 18 to 65, female only, with Breast Hypoplasia and Facial Ageing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the present study is to examine whether enrichment of a fat graft with autologous ex vivo expanded ASC injected into the breast tissue or face, both for cosmetic use, will significantly improve the results of conventional lipofilling and synthetic facial fillers, thereby being able to offer a safer, more natural and long-lasting alternative to current artificial solutions for cosmetic patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Stemform trials

Trials by the same sponsor.

NCT05079243 — Dermal and Subcutaneous Augmentation and Skin Assessment After Fat-, Stem Cell and Scaffold Injections · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03258164 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stemform
Last refreshed: 28 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03258164.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing